Problem

Mass spectrometry is a gold-standard way to characterize complex biological samples, but conventional sample preparation is low-throughput, technically demanding, and often takes hours to days. The result is a bottleneck that limits analytical capacity, creates inconsistent workflows, and prevents biopharma teams from getting timely insight from expensive instruments. The killer use case is advanced biotherapeutics—such as biologics, cell and gene therapies, and other complex modalities—where researchers need rapid, reliable measurements during drug discovery, development, manufacturing, and quality control.

The pain is especially acute because advanced therapies are costly and vulnerable to manufacturing and batch-quality failures. The company’s accelerator-program materials cite treatment costs of roughly $0.5 million to $2 million per patient and argue that manufacturing and quality-control problems account for a substantial share of drug-development failures. Andson’s economic value proposition is therefore to reduce hands-on labor and development time, improve process control, and help make complex therapies faster and less expensive to develop and manufacture.

Product / Service

Andson Biotech sells a mass-spectrometry sample-preparation platform centered on DynaChip X1, a benchtop device that adds proprietary microfluidics to existing mass spectrometers rather than requiring customers to replace those instruments. Its vendor-agnostic detachable interface is designed to integrate into current workflows. The chip performs rapid online buffer exchange and active sample treatment, including separation, isolation, amplification, and removal of interfering salts, metabolites, and detergents from complex biological matrices.

The system supports manual operation for flexible research and automated operation for repeatable, high-throughput workflows. Andson says sample preparation can occur in seconds or in under 15 minutes, while preserving native structures for protein, biomarker, AAV, RNA-therapeutic, native-MS, and charge-detection-MS analysis. The delivery model appears to be an integrated laboratory hardware and workflow platform supported through expert engagement; public materials do not disclose pricing or a separate service or consumables model.

Market

Andson competes in biotools, mass-spectrometry sample preparation, and process-analytical technology for biopharmaceutical research and advanced biomanufacturing. Its target customers include pharmaceutical and biotechnology companies, cell-and-gene-therapy developers, contract development and manufacturing organizations, academic laboratories, and physician-scientists. The closest evidenced alternative is PreOmics, whose automated proteomics sample-preparation systems also reduce hands-on time and integrate with laboratory automation. A market database additionally lists CellFE, Sarcura, and Lunaphore as broader adjacent competitors in advanced-biomanufacturing and life-sciences platforms, although they are not necessarily direct substitutes for DynaChip.

Andson appears to be an early commercializing company rather than a mature scaled vendor. It was founded in 2021, entered Y Combinator’s Winter 2022 cohort, launched DynaChip X1 publicly at ASMS 2025, and reported a $4.7 million funding round plus a $300,000 NIH SBIR Phase 1 grant in October 2025 to expand commercialization and manufacturing. Its 2026 activity includes conference demonstrations, application notes, and technical posters on native MS, charge-detection MS, AAVs, RNA therapeutics, and automated workflows. Public sources reviewed do not disclose revenue or establish that the company is definitively pre-revenue, but the launch, funding, early-adopter development work, and ongoing technical demonstrations indicate commercialization and market validation are still in progress.